Kangjing Xu

Kangjing Xu

Auto-generated profile, based on publicly available information

Kangjing Xu

Clinical Nutrition Service Center Department of General Surgery Nanjing Jinling Hospital Affiliated Hospital of Medical School Nanjing University Nanjing Jiangsu 210000 China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in Cancer Letters
Verified
Journal Article
Open access
KXKangjing Xu
Kangjing Xu
QZQiang Zhang
Qiang Zhang
MCMing Chen
Ming Chen
BLBowen Li
Bowen Li
NWNuofan Wang
Nuofan Wang
HXHao Xu
Hao Xu
N6-methyladenosine (m6A) is a frequently occurring mRNA modification, which regulates mRNA stability, splicing, and translation. However, its role in drug resistance of gastrointestinal stromal tumor (GIST) is not known. Here, we report that m6A modification levels are elevated in imatinib-resistant GIST cells and tissues, and that methyltransferase METTL3 is one of the main protein responsible for this aberrant modification. Increased METTL3 levels contributed to imatinib resistance and worse progression-free survival of GIST patients. Mechanistic studies revealed that METTL3-mediated m6A modification of the 5'UTR of the multidrug transporter MRP1 mRNA promoted drug resistance of GIST by stimulating MRP1 mRNA translation, via binding with YTHDF1 and eEF-1. Further, METTL3 transcription in imatinib resistant GIST cells was activated by ETV1, leading to the increased m6A methylation of MRP1 mRNA. This is the first report showing a novel regulatory mechanism whereby ETV1, METTL3, and the YTHDF1/eEF-1 complex mediate the translation of MRP1 mRNA in an m6A-dependent manner to regulate the intracellular concentration of imatinib and drug resistance of GIST. These findings highlight MRP1 as a new potential therapeutic target for imatinib resistance of GIST.

27 July 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
KXKangjing Xu
Kangjing Xu
ZHZhongyuan He
Zhongyuan He
MCMing Chen
Ming Chen
NWNuofan Wang
Nuofan Wang
DZDiancai Zhang
Diancai Zhang
HXHao Xu
Hao Xu
The pentose phosphate pathway (PPP) plays a critical role in maintaining cellular redox homeostasis in tumor cells and macromolecule biosynthesis. Upregulation of the PPP has been shown in several types of tumor. However, how the PPP is regulated to confer selective growth advantages on drug resistant tumor cells is not well understood. Here we show a metabolic shift from tricarboxylic acid cycle (TCA) to PPP after a long period induction of Imatinib (IM). One of the rate-limiting enzymes of the PPP-phosphogluconate dehydrogenase (PGD), is dramatically upregulated in gastrointestinal stromal tumors (GISTs) and GIST cell lines resistant to Imatinib (IM) compared with sensitive controls. Functional studies revealed that the overexpression of PGD in resistant GIST cell lines promoted cell proliferation and suppressed cell apoptosis. Mechanistic analyses suggested that the protein level of hypoxia inducible factor-1α (HIF-1α) increased during long time stimulation of reactive oxygen species (ROS) produced by IM. Importantly, we further demonstrated that HIF-1α also had positive correlation with PGD, resulting in the change of metabolic pathway, and ultimately causing drug resistance in GIST. Our findings show that long term use of IM alters the metabolic phenotype of GIST through ROS and HIF-1α, and this may contribute to IM resistance. Our work offers preclinical proof of metabolic target as an effective strategy for the treatment of drug resistance in GIST.

1 December 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
QZQiang Zhang
Qiang Zhang
JXJianghao Xu
Jianghao Xu
YQYi Qian
Yi Qian
LCLiang Chen
Liang Chen
QLQingya Li
Qingya Li
ZXZekuan Xu
Zekuan Xu
Gastrointestinal stromal tumors (GIST) are the most prevalent mesenchymal tumors of the digestive tract. To investigate the association of imatinib mesylate plasma concentration with adverse drug reactions (ADRs) and influences of genetic polymorphisms on ADRs in GIST patients taking imatinib, a cohort of GIST patients consecutively treated with imatinib were included in the observational study. Clinical, pathologic and genotype information was recorded at enrollment and blood samples were collected at time as design. The plasma concentration of the imatinib was detected by LC-MS/MS. A questionnaire was used to evaluate the ADRs at each visit. SNPs in 13 genes were analyzed for a possible association with ADRs. The mean plasma trough concentration of 129 patients taking imatinib was 1.45 ± 0.79 μg/ml, average peak concentration was 2.63 ± 1.07 μg/ml. The imatinib concentration in patients treated with 600 mg/day was significantly higher than other dosage groups (P < 0.05). The ADRs were mostly mild. Edema, vomiting, and fatigue were significantly correlated with imatinib concentration (P < 0.05). Mutations of IL13 rs1800925 and CXCL14 rs7716492 were related with the incidence of leukopenia and rash in our research, separately (P < 0.05). We confirmed that with the increase of imatinib concentration, the incidence of edema, vomiting, and fatigue rises as well. Mutations of IL13 rs1800925 and CXCL14 rs7716492 may be the promising biomarkers to predict the ADRs of imatinib. The results of the study are of guiding significance for the use of imatinib in patients with GIST.

1 December 2018 in Surgical Oncology
Verified
Journal Article
Closed access
LCLiang Chen
Liang Chen
QZQiang Zhang
Qiang Zhang
FLFeng-Yuan Li
Feng-Yuan Li
LYLi Yang
Li Yang
DZDian-Cai Zhang
Dian-Cai Zhang
ZXZekuan Xu
Zekuan Xu

2 July 2025 in Advanced Science
Verified
Journal Article
Open access
KXKangjing Xu
Kangjing Xu
RSRongxi Shen
Rongxi Shen
LZLi Zhang
Li Zhang
XGXuejin Gao
Xuejin Gao
XWXinbo Wang
Xinbo Wang
XWXinying Wang
Xinying Wang
Pancreatic ductal adenocarcinoma (PDAC) with cachexia‐related muscle wasting as the main manifestation is associated with poor overall survival. Extracellular vesicles (EVs) are key mediators of inter‐organ communication. Here, EVs and EV‐microRNAs (miRNAs) are identified as mediate PDAC‐skeletal muscle communication. EVs are isolated from PDAC patients, mouse models, patients‐derived organoids, and mouse pancreatic cancer cells. Plasma‐derived EVs from PDAC patients or mice are observed to remarkably induced muscle wasting in vitro and in vivo. Depletion of miRNA cargo in these EVs significantly alleviates their detrimental effects on skeletal muscles. Deep RNA sequencing is conducted to profile differentially expressed miRNAs in plasma EVs from patients with or without PDAC. The findings reveal that the expression of miR‐223‐5p expression in PDAC patients’ plasma EVs is negatively associated with the 3‐year overall survival. Mechanistic studies show that miR‐223‐5p contributes to reduced METTL14 transcription by targeting MAFA, associated with decreased m 6 A methylation in skeletal muscles and muscle wasting. This study highlights the absorption of miRNA in PDAC‐derived EVs by skeletal muscles and reveals a previously unrecognized function of PDAC‐derived EV‐miR‐223‐5p in tumor‐muscle inter‐organ communication, offering novel insight into EV‐miR‐223‐5p‐based diagnostic and therapeutic strategies for PDAC patients with sarcopenia upon further validation.